Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
about
The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.miRNAs: micro-managers of anticancer combination therapies.Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.A perforated microhole-based microfluidic device for improving sprouting angiogenesis in vitro.Ginsenoside-Rb1-Mediated Anti-angiogenesis via Regulating PEDF and miR-33a through the Activation of PPAR-γ Pathway.Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.The Effects of Administrated Sildenafil Citrate on Uterine Luminal Epithelium Height Associated with Ovarian Angiogenesis: An Experimental Animal Study.M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.New data: new options for front-line therapy in NSCLC?Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.Construction of a human monoclonal antibody against bFGF for suppression of NSCLC.Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysisTargeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapyGenetic variation determines VEGF-A plasma levels in cancer patientsCombination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer
P2860
Q33705268-426B4558-1EA0-426D-9B09-13DAE4D01470Q39220891-3EE1276C-FC3A-43E8-9FA4-E8E004D0EDF0Q39285150-E31C5402-4E50-47C8-B669-DD9996ADC785Q39406918-1F2061F2-F3F9-4425-BCF2-F02C1B6723B7Q42706401-C51CC349-7CDD-49F7-A264-EBFB3E9BA9BCQ47150206-38DD5E54-9B05-4E19-82C3-444673205249Q47323319-41380091-E73C-4662-8F65-9711C6D197D7Q47547551-D6DEC6F1-D408-420A-B749-BF0F2F2B8EF3Q48269732-99C095FA-93CC-44C5-808F-07EB60129460Q55008337-7214DAD8-0CD7-43A2-AACB-F7F1323B7404Q55022021-3D6529D7-EF01-404B-8249-48946555E139Q55398181-F9ED4009-54B4-4EBC-8121-2DBCAAB296D3Q55473120-86BBE33D-7F63-49DD-AF1C-98317EDEBDC7Q57071382-23250B7C-38F3-499D-BB07-8B343CAEC11AQ58547872-5F3C4836-7B8B-4219-B582-79474D0149CEQ58612325-3AA0BFF0-7FB4-4C71-93F0-D02B45870913Q58770914-A34BE7F8-722D-4F73-8F9D-1AA4C4F73429
P2860
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Anti-angiogenesis for cancer r ...... mbinations with immunotherapy?
@en
Anti-angiogenesis for cancer r ...... mbinations with immunotherapy?
@nl
type
label
Anti-angiogenesis for cancer r ...... mbinations with immunotherapy?
@en
Anti-angiogenesis for cancer r ...... mbinations with immunotherapy?
@nl
prefLabel
Anti-angiogenesis for cancer r ...... mbinations with immunotherapy?
@en
Anti-angiogenesis for cancer r ...... mbinations with immunotherapy?
@nl
P2093
P2860
P1433
P1476
Anti-angiogenesis for cancer r ...... mbinations with immunotherapy?
@en
P2093
Arjan W Griffioen
Dan G Duda
Rakesh R Ramjiawan
P2860
P2888
P304
P356
10.1007/S10456-017-9552-Y
P577
2017-03-30T00:00:00Z